Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 18/20 | 0.83 |
| ▸ | STAT3 | P40763 | 4/20 | 0.83 |
| ▸ | JAK1 | P23458 | 3/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23753627 | 0.91 | TYK2 (1.00) | TYK2STAT3JAK1JAK2CYP3A4 | |
| SCHEMBL23753633 | 0.89 | TYK2 (0.82) | TYK2STAT3 | |
| SCHEMBL21887376 | 0.82 | TYK2 (0.81) | TYK2STAT3 | |
| SCHEMBL29754461 | 0.81 | TYK2 (0.83) | TYK2STAT3JAK1JAK2CYP3A4 | |
| SCHEMBL20697531 | 0.81 | TYK2 (0.78) | TYK2JAK1 | |
| SCHEMBL20697087 | 0.81 | TYK2 (0.81) | TYK2JAK1 | |
| SCHEMBL23772359 | 0.80 | TYK2 (0.62) | TYK2JAK1 | |
| SCHEMBL24263472 | 0.80 | TYK2 (0.67) | TYK2 | |
| SCHEMBL21887776 | 0.80 | TYK2 (1.00) | TYK2STAT3 | |
| SCHEMBL21811269 | 0.80 | TYK2 (1.00) | TYK2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038705-B | 7- (Methylamino) pyrazolo [1,5-a ] pyrimidine-3-carboxamide compounds | 伊莱利利公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4103565-B1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | LILLY CO ELI (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11634423-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling | ELI LILLY AND COMPANY (US) | 2023-04-25 | — | — | US | disclosed |
| EP-4103565-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | Eli Lilly and Company (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115038705-A | 7- (methylamino) pyrazolo [1,5-a ] pyrimidine-3-carboxamide compounds | 伊莱利利公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2021162942-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210253581-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | ELI LILLY AND COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-20210253581-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | ELI LILLY AND COMPANY | 2021-08-19 | — | — | US | disclosed |
| WO-2021162942-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634423-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling | IFNAR1, IRF3, IFNG | TYK2 381/4885STAT3 16/4885JAK1 6/4885 |
| US-20210253581-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | SSB, IL1R1, SLC5A1 | TYK2 292/4885STAT3 340/4885JAK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.